[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 110 pages | ID: L42D5E695317EN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Low Back Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Drugs In Development, 2022, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 17, 8, 9, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Low Back Pain - Overview
Low Back Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Low Back Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Low Back Pain - Companies Involved in Therapeutics Development
Low Back Pain - Drug Profiles
Low Back Pain - Dormant Projects
Low Back Pain - Discontinued Products
Low Back Pain - Product Development Milestones
Featured News & Press Releases
Jun 30, 2022: BioRestorative Therapies announces first patient enrolled for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)
Jun 22, 2022: BioRestorative Therapies announces clinical trial contract with second site for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)
Jun 13, 2022: BioRestorative Therapies announces clinical site initiation for the company’s phase 2 clinical trial to treat chronic lumbar disc disease (cLDD)
Apr 29, 2022: BioRestorative Therapies hosts principal investigator meeting for its BRTX-100 phase 2 clinical trial to treat chronic lumbar disc disease
Apr 18, 2022: BioRestorative Therapies announces selection of 10 clinical sites for its phase 2 clinical trial to treat chronic lumbar disc disease
Apr 04, 2022: BioRestorative Therapies announces cGMP Cell Manufacturing Facility Certification
Feb 16, 2022: Biorestorative Therapies announces notice of allowance on key patent for its BRTX-100 disc program
Feb 07, 2022: BioRestorative Therapies announces it has initiated its phase 2 clinical trial to treat chronic lumbar disc disease
Jan 04, 2022: BioRestorative Therapies awarded an STTR phase I grant to explore the therapeutic effects of PEG-Peptide hydrogel-encapsulated hypoxic bone marrow stem cells
Aug 20, 2021: Notification of application for manufacturing and marketing approval of the additional indications of “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” for ZICTHORU Tapes (Transdermal, pain treatment NSAID patch, development code: HP-3150) in Japan
Aug 19, 2021: BioRestorative Therapies awarded one of top 10 spine device companies by MedTech Outlook
Jun 30, 2021: Mesoblast provides update on program for chronic low back pain due to degenerative disc disease
Feb 17, 2021: AnGes’ phase 1b results of NF-kappa B Oligo DNA Decoy administration in subjects with chronic discogenic low back pain support advancement into phase 2 clinical study
Feb 10, 2021: Mesoblast phase 3 trial shows that a single injection of Rexlemestrocel-L + Hyaluronic Acid carrier results in at least two years of pain reduction with opioid sparing activity in patients with chronic low back pain due to degenerative disc disease
Dec 07, 2020: Notification of the results of Phase clinical study of HP-3150 for “low back pain, humeroscapular periarthritis, cervico-omo-brachial syndrome and tenosynovitis” in Japan (transdermal, pain treatment NSAID patch)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Low Back Pain, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, 2022
Low Back Pain - Pipeline by Adynxx Inc, 2022
Low Back Pain - Pipeline by Allodynic Therapeutics LLC, 2022
Low Back Pain - Pipeline by Amplicore Inc, 2022
Low Back Pain - Pipeline by AnGes Inc, 2022
Low Back Pain - Pipeline by Axsome Therapeutics Inc, 2022
Low Back Pain - Pipeline by BioRestorative Therapies Inc, 2022
Low Back Pain - Pipeline by Bol Pharma, 2022
Low Back Pain - Pipeline by Camurus AB, 2022
Low Back Pain - Pipeline by Causeway Therapeutics Ltd, 2022
Low Back Pain - Pipeline by Creative Medical Technology Holdings Inc, 2022
Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, 2022
Low Back Pain - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Low Back Pain - Pipeline by Eli Lilly and Co, 2022
Low Back Pain - Pipeline by Epione Therapeutics BV, 2022
Low Back Pain - Pipeline by Ethismos Research Inc, 2022
Low Back Pain - Pipeline by Evero Health Ltd, 2022
Low Back Pain - Pipeline by Gador SA, 2022
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2022
Low Back Pain - Pipeline by Imbrium Therapeutics LP, 2022
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, 2022
Low Back Pain - Pipeline by Indaptus Therapeutics Inc, 2022
Low Back Pain - Pipeline by Laboratorios Silanes SA de CV, 2022
Low Back Pain - Pipeline by MD Biosciences GmbH, 2022
Low Back Pain - Pipeline by Mesoblast Ltd, 2022
Low Back Pain - Pipeline by Navipharm Co Ltd, 2022
Low Back Pain - Pipeline by Neumentum Inc, 2022
Low Back Pain - Pipeline by Pacira BioSciences Inc, 2022
Low Back Pain - Pipeline by Panacea Biotec Ltd, 2022
Low Back Pain - Pipeline by Persica Pharmaceuticals Ltd, 2022
Low Back Pain - Pipeline by Pfizer Inc, 2022
Low Back Pain - Pipeline by Rebus Holdings Inc, 2022
Low Back Pain - Pipeline by Scilex Holding Co, 2022
Low Back Pain - Pipeline by Sclnow Biotechnology Co Ltd, 2022
Low Back Pain - Pipeline by Shionogi & Co Ltd, 2022
Low Back Pain - Pipeline by Spine BioPharma LLC, 2022
Low Back Pain - Pipeline by Stayble Therapeutics AB, 2022
Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, 2022
Low Back Pain - Pipeline by Tris Pharma Inc, 2022
Low Back Pain - Pipeline by Valenta Pharm, 2022
Low Back Pain - Pipeline by Vertanical GmbH, 2022
Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, 2022
Low Back Pain - Pipeline by Xgene Pharmaceutical Inc, 2022
Low Back Pain - Dormant Projects, 2022
Low Back Pain - Dormant Projects, 2022 (Contd..1)
Low Back Pain - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Low Back Pain, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications